Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
OS Therapies (OSTX) announces an exclusive live investor webinar scheduled for February 27, 2025, at 4:15 p.m. ET. The event will feature presentations from CEO Paul Romness and CBO Gerald Commissiong, focusing on the company's pipeline developments.
The company's lead candidate, OST-HER2, has shown significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning it for potential accelerated FDA approval. Their proprietary Tunable Antibody Drug Conjugate (tADC) platform, featuring SiLinker™ technology, has demonstrated preclinical efficacy in ovarian and HER2-positive cancers.
The company highlights potential value drivers including upcoming clinical and regulatory milestones, licensing agreement revenues, and a possible Priority Review Voucher valued at approximately $150 million.
OS Therapies (OSTX) annuncia un webinar esclusivo dal vivo per gli investitori, programmato per il 27 febbraio 2025, alle 16:15 ET. L'evento presenterà interventi del CEO Paul Romness e del CBO Gerald Commissiong, focalizzandosi sugli sviluppi della pipeline dell'azienda.
Il candidato principale dell'azienda, OST-HER2, ha mostrato miglioramenti significativi nella sopravvivenza libera da eventi a 12 mesi per osteosarcoma metastatico ricorrente completamente resecato, posizionandosi per una potenziale approvazione accelerata da parte della FDA. La loro piattaforma proprietaria Tunable Antibody Drug Conjugate (tADC), con tecnologia SiLinker™, ha dimostrato efficacia preclinica nei tumori ovarici e HER2-positivi.
L'azienda evidenzia potenziali fattori di valore, inclusi prossimi traguardi clinici e normativi, ricavi da accordi di licenza e un possibile Voucher per Revisione Prioritaria valutato a circa $150 milioni.
OS Therapies (OSTX) anuncia un seminario web exclusivo en vivo para inversores programado para el 27 de febrero de 2025, a las 4:15 p.m. ET. El evento contará con presentaciones del CEO Paul Romness y del CBO Gerald Commissiong, centrándose en los desarrollos de la cartera de la empresa.
El candidato principal de la empresa, OST-HER2, ha mostrado mejoras significativas en la supervivencia libre de eventos a 12 meses para osteosarcoma metastásico recurrente completamente resecado, posicionándose para una posible aprobación acelerada por parte de la FDA. Su plataforma propietaria Tunable Antibody Drug Conjugate (tADC), que cuenta con la tecnología SiLinker™, ha demostrado eficacia preclínica en cánceres de ovario y HER2-positivos.
La empresa destaca posibles impulsores de valor que incluyen próximos hitos clínicos y regulatorios, ingresos por acuerdos de licencia y un posible Voucher de Revisión Prioritaria valorado en aproximadamente $150 millones.
OS Therapies (OSTX)는 2025년 2월 27일 오후 4시 15분 ET에 예정된 독점 라이브 투자자 웨비나를 발표합니다. 이 행사에서는 CEO Paul Romness와 CBO Gerald Commissiong의 발표가 있을 예정이며, 회사의 파이프라인 개발에 초점을 맞출 것입니다.
회사의 주요 후보인 OST-HER2는 완전 절제된 재발성 전이성 골육종의 12개월 사건 무생존율에서 상당한 개선을 보여주어 FDA의 잠재적인 신속 승인을 위한 위치를 차지하고 있습니다. 그들의 독점 기술인 Tunable Antibody Drug Conjugate (tADC) 플랫폼은 SiLinker™ 기술을 특징으로 하며, 난소암 및 HER2 양성 암에서 전임상 효능을 입증했습니다.
회사는 다가오는 임상 및 규제 이정표, 라이센스 계약 수익, 그리고 약 $150 백만 가치의 우선 심사 바우처와 같은 잠재적인 가치 동인을 강조합니다.
OS Therapies (OSTX) annonce un webinaire exclusif en direct pour les investisseurs prévu pour le 27 février 2025 à 16h15 ET. L'événement comprendra des présentations du PDG Paul Romness et du CBO Gerald Commissiong, axées sur les développements de la pipeline de l'entreprise.
Le principal candidat de l'entreprise, OST-HER2, a montré des améliorations significatives dans la survie sans événement à 12 mois pour l'ostéosarcome métastatique récurrent complètement réséqué, le positionnant pour une approbation accélérée potentielle par la FDA. Leur plateforme propriétaire Tunable Antibody Drug Conjugate (tADC), avec la technologie SiLinker™, a démontré une efficacité préclinique dans les cancers de l'ovaire et HER2-positifs.
L'entreprise souligne les moteurs de valeur potentiels, notamment les prochaines étapes cliniques et réglementaires, les revenus des accords de licence et un possible bon de révision prioritaire d'une valeur d'environ $150 millions.
OS Therapies (OSTX) kündigt ein exklusives Live-Webinar für Investoren an, das für den 27. Februar 2025 um 16:15 Uhr ET geplant ist. Die Veranstaltung wird Präsentationen von CEO Paul Romness und CBO Gerald Commissiong beinhalten, die sich auf die Entwicklungen in der Pipeline des Unternehmens konzentrieren.
Der Hauptkandidat des Unternehmens, OST-HER2, hat signifikante Verbesserungen in der 12-monatigen ereignisfreien Überlebensrate bei rekurrentem, vollständig resezierten metastatischen Osteosarkom gezeigt, was ihn für eine mögliche beschleunigte FDA-Zulassung positioniert. Ihre proprietäre Tunable Antibody Drug Conjugate (tADC) Plattform mit SiLinker™-Technologie hat in präklinischen Studien Wirksamkeit bei Eierstock- und HER2-positiven Krebserkrankungen gezeigt.
Das Unternehmen hebt potenzielle Werttreiber hervor, darunter bevorstehende klinische und regulatorische Meilensteine, Einnahmen aus Lizenzvereinbarungen und einen möglichen Prioritätsüberprüfungs-Voucher im Wert von etwa $150 Millionen.
- Lead candidate OST-HER2 shows significant survival improvements in osteosarcoma
- Potential accelerated FDA approval pathway
- Possible $150M Priority Review Voucher opportunity
- Promising preclinical results in multiple cancer types
- Multiple revenue streams potential through licensing agreements
- Lead candidate still in clinical stage, no approved products
- Commercialization timeline uncertain
The exclusive event, hosted by RedChip Companies, will feature OS Therapies’ Chairman and CEO, Paul Romness, and Chief Business Officer, Gerald Commissiong, who will provide an in-depth update on the Company’s rapidly advancing pipeline. OS Therapies is pioneering groundbreaking immunotherapies and antibody-drug conjugates (ADCs) to address critical unmet needs in pediatric and young adult oncology, as well as a broad range of solid tumors. The Company’s lead candidate, OST-HER2, has demonstrated statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning it as a potential first-in-class treatment with accelerated FDA approval pathways. Additionally, OS Therapies’ proprietary Tunable Antibody Drug Conjugate (tADC) platform, powered by SiLinker™ technology, has shown promising preclinical efficacy in ovarian and other HER2-positive cancers. With multiple upcoming clinical and regulatory milestones, potential revenue streams from licensing agreements, and a possible Priority Review Voucher (PRV) worth approximately
A live Q&A session with Romness and Commissiong will follow the presentation.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_-ovpJStsQeGoBUPjuUcdlA#/registration
Questions can be pre-submitted to OSTX@redchip.com or online during the live event.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226496977/en/
Jack Doll
+1.571.243.9455
irpr@ostherapies.com
Dave Gentry
RedChip Companies, Inc.
+1.407.644.4256
OSTX@redchip.com
Source: OS Therapies
FAQ
When is OS Therapies (OSTX) hosting their investor webinar and who will present?
What are the key clinical developments for OSTX's lead candidate OST-HER2?
What is the estimated value of the Priority Review Voucher (PRV) that OSTX might receive?
What therapeutic areas does OSTX's tADC platform target?
